Alpha-type 1-polarized dendritic cells loaded with apoptotic allogeneic myeloma cell line induce strong CTL responses against autologous myeloma cells

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Annals of Hematology

• Publication date

  2010-03-18

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/s00277-010-0931-3PMID 20238114
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Melan-A/MART1 Analog Peptide Triggers Anti-myeloma T-cells Through Crossreactivity With HM1.24

  2009cited by this paper
• The role of high-dose therapy with autologous stem cell support in the era of novel agents.

  2009cited by this paper
• Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma

  2009cited by this paper
• Gene Expression Profiling and Real-Time PCR Analyses Identify Novel Potential Cancer-Testis Antigens in Multiple Myeloma1

  2009cited by this paper
• The dysfunction and abnormal signaling pathway of dendritic cells loaded by tumor antigen can be overcome by neutralizing VEGF in multiple myeloma.

  2009cited by this paper
• Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation.

  2008cited by this paper
• Type 1‐polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia

  2008cited by this paper
• Analysis and Characterization of Antitumor T-cell Response After Administration of Dendritic Cells Loaded With Allogeneic Tumor Lysate to Metastatic Melanoma Patients

  2008cited by this paper
• Induction of multiple myeloma-specific cytotoxic T lymphocyte stimulation by dendritic cell pulsing with purified and optimized myeloma cell lysates

  2007cited by this paper
• CD38 orchestrates migration, survival, and Th1 immune response of human mature dendritic cells.

  2006cited by this paper
• Optimizing immunotherapy in multiple myeloma: Restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells.

  2006cited by this paper
• Dendritic Cells Loaded With Killed Allogeneic Melanoma Cells can Induce Objective Clinical Responses and MART-1 Specific CD8+ T-cell Immunity

  2006cited by this paper
• Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway.

  2005cited by this paper
• Allogeneic gastric cancer cell-dendritic cell hybrids induce tumor antigen (carcinoembryonic antigen) specific CD8[+] T cells

  2005cited by this paper
• Dendritic Cells Fused with Allogeneic Colorectal Cancer Cell Line Present Multiple Colorectal Cancer–Specific Antigens and Induce Antitumor Immunity against Autologous Tumor Cells

  2005cited by this paper
• Allogeneic gastric cancer cell-dendritic cell hybrids induce tumor antigen (carcinoembryonic antigen) specific CD8+ T cells

  2004cited by this paper
• Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma

  2004cited by this paper
• alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity.

  2004cited by this paper
• Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes.

  2003cited by this paper
• Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6.

  2002cited by this paper
• Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy.

  2002cited by this paper
• Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12.

  2002cited by this paper

• Phase II Trial of Adjuvant Dendritic Cell Vaccine in Combination with Celecoxib, Interferon-α, and Rintatolimod in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastases

  2021cites this paper
• Immunotherapeutic Strategies for Multiple Myeloma

  2020cites this paper
• Feasibility of dendritic cell-based vaccine against glioblastoma by using cytoplasmic transduction peptide (CTP)-fused protein antigens combined with anti-PD1

  2020cites this paper
• Enhanced anti-tumor effects of dendritic cells against glioblastoma by using cytoplasmic transduction peptide (CTP)-fused recombinant protein combined with anti-PD1

  2019cites this paper
• The Deubiquitinase Inhibitor b-AP15 and Its Effect on Phenotype and Function of Monocyte-Derived Dendritic Cells

  2019cites this paper
• Immunotherapy for the treatment of multiple myeloma.

  2017cites this paper
• Recent advances in multiple myeloma: a Korean perspective

  2016cites this paper
• Dendritic cells induce specific cytotoxic T lymphocytes against prostate cancer TRAMP-C2 cells loaded with freeze- thaw antigen and PEP-3 peptide.

  2015cites this paper
• Dendritic Cell-Based Cancer Immunotherapy against Multiple Myeloma: From Bench to Clinic

  2015cites this paper
• Immunotherapy strategies in multiple myeloma.

  2014cites this paper
• Generation of multiple peptide cocktail-pulsed dendritic cells as a cancer vaccine.

  2014cites this paper
• A Bacterial Flagellin in Combination With Proinflammatory Cytokines Activates Human Monocyte-derived Dendritic Cells to Generate Cytotoxic T Lymphocytes Having Increased Homing Signals to Cancer

  2014cites this paper
• Tolerogenic dendritic cells: molecular and cellular mechanisms in transplantation

  2014cites this paper
• Cellular Immunotherapy Using Dendritic Cells in Multiple Myeloma: New Concept to Enhance Efficacy

  2013cites this paper
• Generation of Potent Cytotoxic T Lymphocytes Against Castration‐Resistant Prostate Cancer Cells by Dendritic Cells Loaded With Dying Allogeneic Prostate Cancer Cells

  2013cites this paper
• Immunotherapy Using Dendritic Cells against Multiple Myeloma: How to Improve?

  2012cites this paper
• Evolution of cellular immunotherapy: from allogeneic transplant to dendritic cell vaccination as treatment for multiple myeloma.

  2012cites this paper
• Complex evaluation of human monocyte-derived dendritic cells for cancer immunotherapy

  2012cites this paper
• Cellular immunotherapy using dendritic cells against multiple myeloma

  2012influential citation
• Novel Strategies for Immunotherapy in Multiple Myeloma: Previous Experience and Future Directions

  2012cites this paper
• Optimal culture conditions for the generation of natural killer cell-induced dendritic cells for cancer immunotherapy

  2011cites this paper
• Immunotherapeutic potential of oncolytic vaccinia virus

  2011cites this paper
• Successful cross-presentation of allogeneic myeloma cells by autologous alpha-type 1-polarized dendritic cells as an effective tumor antigen in myeloma patients with matched monoclonal immunoglobulins

  2011influential citation
• Induction of myeloma-specific cytotoxic T lymphocytes responses by natural killer cells stimulated-dendritic cells in patients with multiple myeloma.

  2011cites this paper
• Multiple myeloma in Korea: past, present, and future perspectives. Experience of the Korean Multiple Myeloma Working Party

  2010cites this paper